Antimicrobial Treatmdent of "Complicated" Intra-Abdominal Infections and The New IDSA Guidelines - A Commentary and an Alternative European Approach According to Clinical Definitions by Eckmann, C et al.
March 28, 2011 115 Eu  Ro  PE  An JouR  nAl of MEd  I  cAl RE  sEARcH
Abstract
Recently,  an  update  of  the  IdsA  guidelines  for  the
treatment  of  complicated  intraabdominal  infections
has been published. no guideline can cater for all vari-
ations in ecology, antimicrobial resistance patterns, pa-
tient characteristics and presentation, health care and
reimbursement systems in many different countries. In
the short time the IdsA guidelines have been avail-
able, a number of practical clinical issues have been
raised  by  physicians  regarding  interpretation  of  the
guidelines.  the  main  debatable  issues  of  the  new
IdsA guidelines are described as follows:
the authors of the IdsA guidelines present recom-
mendations for the following subgroups of „compli-
cated“  IAI:  community-acquired  intra-abdominal  in-
fections  of  mild-to-moderate  and  high  severity  and
health care-associated intra-abdominal infections (no
general treatment recommendations, only information
about antimicrobial therapy of specific resistant bacte-
rial isolates). from a clinical point of view, „compli-
cated“ IAI are better differentiated into primary, sec-
ondary  (community-acquired  and  postoperative)  and
tertiary peritonitis. those are the clinical presentations
of IAI as seen in the emergency room, the general
ward and on Icu. future antibiotic treatment studies
of IAI would be more clinically relevant if they in-
cluded patients in studies for the efficacy and safety of
antibiotics for the treatment of the above mentioned
forms of IAI, rather than conducting studies based on
the vague term „complicated“ intra-abdominal infec-
tions.
the new IdsA guidelines for the treatment of re-
sistant bacteria fail to mention many of new available
drugs,  although  clinical  data  for  the  treatment  of
„complicated IAI“ with new substances exist. further-
more, treatment recommendations for cIAI caused by
vRE are not included. this group of diseases com-
prises enough patients (i.e. the entire group of postop-
erative and tertiary peritonitis, recurrent interventions
in bile duct surgery or necrotizing pancreatitis) to pro-
vide specific recommendations for such antimicrobial
treatment.
A panel of European colleagues from surgery, in-
tensive care, clinical microbiology and infectious dis-
eases has developed recommendations based on the
above mentioned clinical entities with the aim of pro-
viding clear therapeutic recommendations for specific
clinical diagnoses. An individual patient-centered ap-
proach for this very important group of diseases with
a substantial morbidity and mortality is essential for
optimal antimicrobial treatment. 
PREfAcE
Recently,  an  update  of  the  IdsA  guidelines  for  the
treatment  of  complicated  intraabdominal  infections
has been published [1]. this comprehensive document
has been thoroughly collated by reknown experts in
the  field  and  its  influence  extends  well  beyond  the
usA, making it a worldwide gold standard immediate-
ly after publication. However, it is a guideline, and no
guideline can cater for all variations in ecology, antimi-
crobial resistance patterns, patient characteristics and
presentation, health care and reimbursement systems
in  many  different  countries.  In  the  short  time  the
guidelines  have  been  used  clinically,  several  areas  of
confusion have arisen and been identified. following
such observations and personal experiences, a panel of
European colleagues from surgery, intensive care, clin-
ical microbiology and infectious diseases met several
times to discuss the problematic issues associated with
the new IdsA guidelines. 
the following recommendations and observations
on a very important group of diseases with a substan-
tial morbidity and mortality are not meant to stand in
contradict to the IdsA guidelines, but rather to add
some information and guidance for the management
of complicated intra-abdominal infections where the
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4) Eckmann_Umbruchvorlage  14.03.11  11:58  Seite 115authors believe it could be of value for clinicians treat-
ing those patients. the main contentious issues in the
recent IdsA guidelines are as follows:
IssuE 1 – dEfInItIons
the IdsA defines complicated and uncomplicated in-
tra-abdominal infections. In complicated intra-abdom-
inal infections the infection extends beyond the hol-
low viscus of origin into the peritoneal space and is
associated with either abscess formation or peritonitis,
whereas  an  uncomplicated  infection  involves  intra-
mural inflammation of the gastrointestinal tract [1]. 
this appears to be an artificial differentiation which
does not always translate into clinical reality. for in-
stance, a patient with an appendicitis with a tip of fib-
rin on top of the appendix (assumed mortality: 0.5-
2%) has a „complicated“ IAI according to these defin-
itions whereas a clostridium difficile-associated colitis
with PcR-ribotype 027 (mean mortality: 20-30%) is an
„uncomplicated“ IAI following the IdsA criteria. A
complicated IAI is defined best by its course and clini-
cal  severity  and  not  necessarily  by  its  local  extent.
therefore, the above mentioned definition should be
used with caution. 
the authors of the IdsA guidelines present treat-
ment recommendations for the following briefly de-
fined  subgroups  of  „complicated“  IAI:  community-
acquired intra-abdominal infections of mild-to-moder-
ate and high severity and health care-associated intra-
abdominal infections. there are no general empirical
treatment recommendations, only information on an-
timicrobial therapy of specific resistant bacteria. 
from a clinical point of view, „complicated“ IAI
are better differentiated into primary, secondary (com-
munity-acquired and postoperative) and tertiary peri-
tonitis [2]. those are the clinical presentations of IAI
as seen in the emergency room, the general ward and
on  Icu.  In  recently  published  manuscripts  dealing
with  critical  conditions  in  IAI  the  authors  have  re-
ferred  to  the  above  mentioned  definitions  [3,  4].
therefore, it is much closer to clinical conditions if
guidelines follow this classification. the panel believes
that  further  studies  on  antimicrobial  agents  in  IAI
should not longer refer to „complicated“ and „uncom-
plicated“ as this leads to a mixture of very different
clinical entities and therefore may weaken the value of
these studies. It would be more accurate in future to
include patients in studies for the efficacy and safety
of  antibiotics  for  the  treatment  of  community-ac-
quired secondary peritonitis, postoperative secondary
peritonitis and tertiary peritonitis, respectively, rather
than  to  conduct  studies  based  on  the  vague  term
„complicated“ intra-abdominal infections.
IssuE 2 – REsIstAnt bActERIA, AntIbIotIc
dIvERsIty And AntIbIotIc stEwARdsHIP
due to the substantially increasing, but geographically
varying  prevalence  of  resistant  Gram-positive  and
Gram-negative  pathogens  there  have  been  numerous
efforts to encourage research in the development of
new antimicrobials with efficacy and safety in this field
[5]. As a result, new antibiotics with efficacy against re-
sistant bacteria (linezolid against MRsA and vRE, dap-
tomycin  against  MRsA  and  vRE,  tigecycline  against
MRsA,  vRE,  Esbl-producing  Enterobacteriaceae,
carbapenem-resistant bacteria) have shown activity in
vitro and in vivo [6, 7, 8]. unfortunately, the new IdsA
guidelines for the treatment of resistant bacteria sum-
marized in a table about treatment of „health-care as-
sociated complicated intra-abdominal infection“ fail to
mention any of these drugs [1], although clinical data
for the treatment of „complicated IAI“ exist for line-
zolid and tigecycline which is approved for „cIAI“ [8-
10, 11*, 12* (*=published after the IdsA guidelines
have been published)]. certainly, the clinical data for all
of the mentioned drugs in „cIAI“ are weak and con-
cerns about an increased mortality rate under tigecy-
cline treatment remain (for „cIAI“ the mortality rate
was 0.7% (non-significantly) higher in the tigecycline
group than in the comparator group) [8, 13]. However,
randomized  double  blind  trials  for  the  efficacy  and
safety  of  an  antibiotic  in  the  treatment  of  „cIAI“
caused by resistant organisms such as MRsA, vRE or
Esbl-producing Enterobacteriaceae are unlikely to be
carried out. consequently, as long as more than one
therapeutic  alternative  is  available,  the  application  of
antibiotic diversity appears to be a very useful tool in
order to reduce the antibiotic selective pressure on any
substance as a part of an antibiotic stewardship pro-
gram [14-17]. It is inappropriate to restrict treatment
recommendations  for  MRsA  in  cIAI  to  vancomycin
and  for  Esbl-producing  Enterobacteriaceae  to  car-
bapenems  and  pipera  cillin/tazobactam  [1].  A  recom-
mendation that includes the existing variety of antibi-
otics with clinical data from the treatment in IAI (van-
comycin, linezolid and tigecycline for MRsA, linezolid
and  tigecycline  for  vRE,  carbapenems,  piperacillin/
tazobactam,  tigecycline  and  colistin  for  Esbl,  see
table 5) provides a choice between substances in terms
of an individual approach to every patient with mini-
mization of toxicity and resistance development.
IssuE 3 – vRE, cARbAPEnEMAsE-PRoducInG
PAtHoGEns, AcinetobActer sPP.
the new IdsA guidelines do not include any treat-
ment recommendations for cIAI caused by vRE. the
authors of the guideline describe only patients such as
liver transplant recipients with an intra-abdominal in-
fection originating in the hepatobiliary tract or patients
known to be colonized with vRE as a risk factor. In
fact, the value of the administration of an anti-entero-
coccal agent for the prognosis of patients with IAI is
discussed controversial, but the entire group of post-
operative  and  tertiary  peritonitis,  recurrent  interven-
tions in bile duct surgery, necrotizing pancreatitis, and
those  with  valvular  heart  disease  or  prosthetic  in-
travascular  materials  have  a  substantial  risk  (varying
from country to country and from hospital to hospi-
tal) for involvement of vRE which is a risk factor for
treatment  failure  and  death.  this  group  of  diseases
comprises enough patients to provide specific recom-
mendations  for  such  antimicrobial  treatment.  these
are shown in table 5, as well as recommendations for
the  treatment  of  cabapenemase-producing  bacteria
and Acinetobacter spp.
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Intra  abdominal  infections  (IAI)  are  common.  na-
tional  and  international  databases  show  that  one  in
four cases of severe sepsis or septic shock is caused
by  IAI.  It  is  the  second  most  common  focus  of 
septic shock after pulmonary causes [18-20]. Almost
90%  of  all  intra  abdominal  infections  are  so  called
secondary peritoneal infections and require primarily
a surgical approach (i.e. appendectomy for a perforat-
ed  appendicitis).  there  is  overwhelming  evidence 
for antibiotic treatment compared to placebo in this
disease  group  [21].  However,  primary  inadequate 
and inappropriate antibiotic regimens have a substan-
tially worse prognostic outcome for patients with IAI
and cause substantial increase in health care costs [22-
24]. 
Recommendations for the empirical antibiotic treat-
ment of IAI are based on a multitude of prospective
randomized and controlled studies. complicated IAI,
by definition, are not necessarily a severe disease. In
trials designed for showing equivalence of antibiotics
or used for registration of new antibiotics the ‘usual’
intra-abdominal infections enrolled are associated with
an  APAcHE  II  score  between  4  and  6.  Aiming  to
show a therapeutic equivalence, even the results of a
recent cochrane analysis were not able to demonstrate
superiority  of  any  particular  antibiotic  or  treatment
scheme [21]. 
In this manuscript every antibiotic / group of an-
tibiotics is provided with a specific level of evidence
and  strength  of  recommendation  shown  which  is
modified after [25, 26] and shown in table 1. the level
of evidence follows the quality of studies for the spe-
cific drug, the strength of recommendation takes con-
siderations of toxicity and potential for development
of resistance into account.
choosing the right antibiotics for a particular pa-
tient should be influenced by a multitude of factors,
i.e. patients (co-morbidities, immuno-suppression, pre-
vious  antimicrobial  treatment),  expected  microbial
spectrum, local bacterial and resistance statistics, ease
of application, level of toxicity and costs. 
In recent years the evaluation of antibiotic treat-
ment schemes were improved through differentiating
peritonitis  subgroups.  these  guidelines  follow  the
clinical definitions of primary, secondary and tertiary
peritonitis  (tables  2-4),  based  on  [35].  Increasing
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table 1. levels of evidence and strength of recommendation modified after [25, 26].
Level of evidence Explanation
1 Meta-analysis of randomized controlled trials, good quality randomized controlled trials or ‘all
or none’ studies in which no treatment is not an option
2 ‘low quality’ randomized controlled trials (<80% follow up), meta-analysis of good quality
prospective ‘cohort studies’ or well designed controlled study without randomization
3 Good quality retrospective ‘case-control’-studies or comparative studies
4 consensus, usual practise, disease-oriented evidence, and/or expert opinion
Strength of recommendation Explanation
A use of agent is recommended (“do it”)
b use of agent should be considered (“probably do it”)
c use of agent may be considered (“is not recommended”)
table 2. Recommendations for initial therapy of primary and cAPd-associated peritonitis. *= use antibiotic only if local sus-
ceptibility rates are ≥90%.
Diagnosis Likely organisms Initial therapy Level of evidence Strength of 
recommenddation
Spontaneous bacterial  Escherichia coli  ceftriaxon 3A
peritonitis  Enterococci  Acylaminopenicillin/blI  3A
(mostly liver cirrhosis  Klebsiella spp. ciprofloxacin*  3A
associated) levofloxacin* 3b
CAPD - associated  s. aureus cephalosporin group 2  3A
peritonitis Enterococci with/without 
other streptococci  ciprofloxacin* 
Escherichia coli
Enterobacteriaceae vancomycin + Gentamicin 3A
Pseudomonas see table 5
Acinetobacter
MRsA, vRE see table 5
Esbl
candida sp. see table 6
4) Eckmann_Umbruchvorlage  14.03.11  11:58  Seite 117numbers  of  IAI  caused  by  multi-resistant  agents
(MRsA,  vRE,  Esbl-producing  Enterobacteriaceae)
or difficult treatable species (i.e. Pseudomonas, candi-
da) were accommodated by extra data (tables 5, 6). 
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table  3.  Recommendations  for  initial  therapy  of  different  forms  of  secondary  peritonitis.  blI=beta-lactamase  inhibitor,
MRsA=Methicillin resistant s. aureus, vRE= vancomycin-resistant Enterococcus spp., Esbl= extended spectrum beta-lacta-
mase producing  species, met.=metronidazole, + = combination with antibiotics covering gram negative and anaerobic species
required, #= combination with Pseudomonas-active antibiotics required if Pseudomonas is suspected; *=use antibiotic only if
local susceptibility rates are ≥90%.
Diagnosis Likely organism Initial therapy  Level of evidence Strength of 
recommendation
Community-acquired  Enterobacteriaceae cephalosporin group 2 /3a   1/1 A/A
localized peritonitis  Enterococci + metronidazole
(e.g. recently perforated  Anaerobes Aminopenicillin/blI 1A
appendicitis) Acylaminopenicillin/blI 1A
ciprofloxacin* + Met. 1b
Community-acquired  Enterobacteriaceae cephalosporin group 3a + 1A
diffuse peritonitis  Enterococci metronidazole
+- risk factors  Anaerobes Acylaminopenicillin/blI 1A
(e.g. perforated colonic  Imipenem-cilastatin  1A
carcinoma) Meropenem 1A
doripenem 1A
Ertapenem 1A
Moxifloxacin 1A
tigecycline 1b
cefepime 1b
ciprofloxacin*+ Met. 1b
levofloxacin* + Met. 1b
Nosocomial  Enterobacteriaceae Imipenem-cilastatin 1A
postoperative, post- Enterococci Meropenem 1A
traumatic or post- Anaerobes doripenem 1A
interventional diffuse  staphylococci Acylaminopenicillin/blI 1A
peritonitis  Ertapenem# 1A
(e.g. anastomotic  tigecycline# 2A
leakage following  Moxifloxacin 1b
ileotransversostomy) MRsA
vRE see table 5
Esbl
candida spp. see table 6
table 4. Recommendations for the initial therapy of tertiary peritonitis. #= combination therapy with pseudomonas-active
agent required if Pseudomonas is suspected
Diagnosis Likely organism Initial therapy Level of evidence Strength of 
recommendation
Persisting peritonitis  Enterobacteriaceae Imipenem-cilastatin  2A
despite adequate  (Enterococci)  Meropenem 2A
surgical and initial  (staphylococci)  Acylaminopenicillin/blI 2A
antimicrobial therapy Anaerobes tigecycline# 2A
Ertapenem# 4b
ceftriaxone+  4b
Metronidazole
MRsA, vRE
Esbl see table 5
Pseudomonas spp.
candida spp. see table 6
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duration of IAI. the following recommendations are
based on therapy intervals stated in randomised stud-
ies,  diagnostic  characteristics  of  certain  infectious
agents (i.e. candida sp.), whether the infection is local
or systemic, as well as the author’s experience. when-
ever the patient is improving clinically and inflamma-
tory  signs  decreasing,  the  antibiotic  discontinuation
should be considered, especially to prevent pathogen
selection and undesirable side effects. Has a treatment
success, even in severe infections, not occurred after 7
days, the treatment discontinuation should be consid-
ered in favour of repeated culture sampling, especially
to prevent selection of multi-resistant pathogens and
possible toxic side effects. Additional imaging proce-
dures, search of other foci of infection, need of sub-
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table 5. calculated and targeted antibiotic therapy with suspected or proven IAI with multi-resistant agents (MRsA=Methicillin
resistant  s.  aureus,  vRE=  vancomycin-resistant  Enterococcus  spp.,  Esbl=  extended  spectrum  beta-lactamase  producing
species,  + = combination with antibiotics covering gram negative and anaerobic species required, # = combination with
Pseudomonas-active antibiotics required if Pseudomonas is suspected; Ⓤ = no monotherapy, * =use antibiotic only if local sus-
ceptibility rates are ≥90%.
Agent Antibiotic Level of evidence Strength of recommendation
MRSA tigecycline# 2A
linezolid+ 3A
daptomycin+ 4c
vancomycin+ 4b
cotrimoxazole+ 4c
VRE tigecycline# 2A
linezolid+ 3A
ESBL-producing  Imipenem 3A
(E. coli, Klebsiella spp.) Meropenem 3A
doripenem 3A
Ertapenem# 3A
tigecycline# 2A
Acylaminopenicillin/blI 3A
fosfomycinⓊ 4b
Pseudomonas spp. Imipenem 4A
Meropenem 4A
doripenem 4A
Acylaminopenicillin/blI 4A
cefepim 4A
AminoglycosideⓊ 4b
ciprofloxacin* 4A
levofloxacin* 4A
Acinetobacter spp. colistin 2A
tigecycline# 4A
Carbapenemase- tigecycline# 4A
producing species colistin 4b
(i.e. KPC)
table 6. treatment strategy with suspected or proven invasive intra-abdominal mycotic infection with candida spp. 
Diagnosis Initial therapy Level of evidence  Strength of recommendation
Colonization with Candida spp. none 3A
Suspected or proven invasive  fluconazole 3A
mycosis: stable patient voriconazole 4b
Suspected or proven invasive  Echinocandin  4A
mycosis: instable patient (Anidulafungin, 
caspofungin, Micafungin)
If candida spp. is
fluconazole-susceptible,
step-down therapy to
fluconazole or 3A
voriconazole  3A
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this setting.
Peritonitis as the most frequent form of IAI consti-
tutes a very complex reaction of the peritoneum and
its histological structure to bacterial, viral, fungal or
chemical stimuli. three main forms of peritonitis can
be differentiated according to its causative pathogene-
sis, its spectrum of pathogens and according to surgi-
cal and antimicrobial therapy [2]:
PRIMARy PERItonItIs
Primary (spontaneous bacterial) peritonitis (sbP) con-
stitutes only about 1% of all peritonitis cases [27]. the
juvenile form has its origin in a hematogenous spread
infection,  usually  streptococci,  pneumococci  or  very
rarely Haemophilus influenzae. In adults in the majori-
ty of cases (70%), sbP is associated with ascites and
alcohol-associated liver cirrhosis or other causes of a
reduced immune system (30%). It is diagnosed when
the ascites neutrophil count exceeds 250/ul [28]. In
most  cases,  it  constitutes  a  mono  infection  through
translocation  or  hematogenous  spreading.  In  studies
portraying the clinical setting realistically, only in about
35% of cases the causative agent is isolated and then
shared among e. coli, Klebsiella sp., staphylococci, en-
terococci or streptococci. the insufficient rate of bac-
terial detection is explained through the fact that in
the clinical setting only about 50% of cases with sbP
ascites is harvested for cultural testing [28].
Primary peritonitis in tuberculosis is usually caused
by hematogenous spreading. 
Randomised  trials  for  sbP  treatments  are  rare.
Most  of  the  studies  are  retrospective  works  that
should  be  classified  as  treatment  surveillance  trials.
the following recommendations thus do not support
higher evidence levels (table 2). Antibiotics used were
ceftriaxone,  cefotaxime,  ceftazidime  as  well  as  acy-
laminopenicillins with anti-beta-lactamase activity [28-
31]. with these agents clinical cure rates of up to 83%
were achieved. 
PERItonItIs AssocIAtEd wItH cAPd
cAPd associated peritonitis is usually caused by tube-
or  catheter  contamination.  Most  frequently  involved
causative agents are coagulase-negative staphylococci
and  Staphylococcus  aureus.  other  less  frequent  in-
volved agents are e. coli, enterococci, other strepto-
cocci, Pseudomonas aeruginosa, anaerobes, enterobacter
spp., Acinetobacter sp., Proteus sp. or candida species
[32]. uncomplicated cases can be treated successfully
by  adding  antimicrobial  agents  to  the  dialysis  fluid.
only in rare and serious cases antibiotics have to be
given not only into the peritoneum but parenteral as
well.  In  patients  with  renal  failure  applicated  drugs
have to be monitored and doses adjusted. the recom-
mended empirical therapy is usually started with van-
comycin plus gentamicin or a group 2 cephalosporin
with or without ciprofloxacin [33]. the therapy should
be then continued after bacteriology results have been
obtained. In cases with proven MRsA-, MRsE- and
Enterococcae  (incl.  vRE)  infections,  antibiotics  in
table 4 should be applied. In cases with proven my-
cotic cAPd-peritonitis, agents in table 5 should be
considered. If the infection is not controlled within 7
days, the peritoneal dialysis catheter must be removed
and additional investigations performed in search for a
reason of persistent infection.
sEcondARy PERItonItIs
secondary  peritonitis  is  caused  by  a  gastrointestinal
(GI) perforation and is with 80-90% by far the most
frequent  IAI.  Per  definition,  a  surgical  intervention
(i.e.  appendectomy  in  perforated  appendicitis)  must
follow. A primary surgical intervention with definitive
abdominal  closure  and  clinical  surveillance  has  be-
come the treatment of choice for most patients with
secondary  peritonitis  [34].  secondary  peritonitis  can
be  further  differentiated  into  community  acquired
(about 70% of all sP) and postoperative (about 30%). 
coMMunIty AcquIREd sEcondARy
PERItonItIs
community acquired secondary peritonitis is always a
mixed  infection.  Apart  from  surgical  interventions
aiming to repair the bacterial leakage, a calculated an-
tibiotic therapy should always be initiated pre-opera-
tively or intra-operatively. Its bacterial spectrum can
differ  depending  on  the  site  of  the  perforation  or
leakage. Most frequently involved bacteria are e. coli,
bacteroides  fragilis and other anaerobes and entero-
cocci. 
following  gastro-duodenal  perforations  bacterial
counts are usually low (<103/ml) and aerobic/anaero-
bic mixed infections rather rare. Perforations of the
biliary system or jejunum usually produce intermediate
bacterial  counts  (103 -  105)  and  a  mixed  aerobic/
anaerobic infection in 50% of cases. colon- or ileum
perforations produce high bacterial counts (>105) and
almost always a mixed aerobic/anaerobic bacterial in-
fection [35]. 
localised acute peritoneal infections (i.e. acute ap-
pendicitis  with  existing  peritoneal  contamination  of
less than 6 hours) show usually a clear or cloudy exu-
date.  usually  available  antibiotics  are  aminopeni-
cillin/blI, acylaminopenicillin/blI, ertapenem, alter-
natively group 2 cephalosporins in combination with
metronidazole or ceftriaxone. therapy duration can be
reduced to 1-2 days in localized cases with a short (<6
hours)  duration  of  peritoneal  contamination  (see
table 3). A two to four hours existing diffuse peritoni-
tis,  which  could  not  be  sufficiently  controlled  and
showing a putrid and faecal exudate, should be treated
with  single  agents  or  a  combination  of  agents  with
broad spectrum activity. the empirical therapy should
include acylaminopenicillin/blI or group 1 (ertapen-
em)  or  group  2  (imipenem/cilastatin,  meropenem,
doripenem) carbapenems. Alternatively combinations
of  metronidazole  with  group  2,  3a  or  4  cephalo  -
sporins, ciprofloxacin, levofloxacin or a moxifloxacin
monotherapy. Antibiotics covering the enterococci are
usually not required in community acquired intra-ab-
dominal infections. Antibiotic treatment of enterococ-
ci is recommended in postoperative IAI or seriously ill
patients [36, 37]. 
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monotherapy versus lactam-aminoglycoside antibiotic
combination therapy for sepsis did not show any addi-
tional positive effects for aminoglycoside combination
therapy [38]. Aminoglycosides still have their place in
combination with broad spectrum sensitive beta-lac-
tam-inhibitors  (especially  carbapenems,  Acy-
laminopenicillin/blI)  for  the  treatment  of  Pseudo  -
monas spp. [39, 40]. variable kinetic parameters as well
as oto- and nephrotoxicity require repeated serum-lev-
el controls. 
PostoPERAtIvE PERItonItIs
Postoperative  peritonitis  is  a  nosocomial  secondary
peritonitis form and defined as an infectious abdomi-
nal complication following surgical interventions (i.e.
anastomotic  insufficiency  following  anterior  rectum
resection)  [2].  Postoperative  infections  compared  to
tertiary peritoneal infections always require a surgical
approach [36, 37, 41]. because of diagnostic and ther-
apeutic difficulties as well as worse prognostic factors,
it has its own entity among secondary peritoneal infec-
tions [4]. the majority of patients are usually already
covered by antibiotics when the diagnosis is made and
the  microbial  causes  of  such  peritonitis  tend  to  be
multiple  drug-resistant  (MdR)  including  enterococci
(incl.  vRE),  Gram-negative  organisms  (Esbl  or
Ampc or carbapenemase-producer), MRsA and can-
dida species. 
thus the choice of antibiotics in these cases needs
to be influenced by local epidemiology and suscepti-
bility of isolates. Appropriate agents may be carbapen-
ems,  tigecycline,  piperacillin/tazobactam  or  moxi-
floxacin  depending  on  microbial  findings  (table  3)
Antifungal treatment is recommended for proven fun-
gal infections (table 6). 
tERtIARy PERItonItIs
tertiary peritonitis is a persistent intra-abdominal in-
fection without a surgically treatable focus, following
an earlier surgical intervention and source control [2].
In most cases the infection is maintained because of a
state of immunodeficiency and or due to resistant bac-
teria selection following antibiotic treatments. Patients
who might develop tertiary peritonitis are very diffi-
cult to identify. compared to cases of secondary peri-
tonitis  there  are  significant  higher  MPI-score,  sAPs
II-score  and  elevated  cRP-serum  levels  [41].  this
form of nosocomial peritonitis shows a similar shifted
bacterial spectrum which is also found in postopera-
tive  secondary  peritonitis.  frequently  found  bacteria
include  enterococci  (incl.  vRE),  staphylococci  incl.
MRsA,  enterobacteriaceae,  anaerobes  and  candida
species  [36].  compared  to  postoperative  peritonitis,
the tertiary form does not require any surgical inter-
vention [2, 4] but this point is difficult to assess until a
non-contributory surgical intervention proves that the
patient  has  indeed  a  tertiary  peritonitis.  Antibiotics
that may work in this subgroup of patients are either
group 1 or 2 carbapenems, tigecycline (in combination
with a Pseudomonas-active agent if a relevant patho-
genetic  role  of  Pseudomonas spp.  is  suspected  or
proven), acylaminopenicillinwithbeta-lactam-inhibitor
or group  3a  cephalosporins  in  combination  with
metronidazole (see table 4) [36, 42]. treatment rec-
ommendations for invasive fungal intra-abdominal in-
fections are found in table 6. Post-peritonitis abscess
formations should be drained ct-guided and treated
according to its antimicrobial spectrum. 
dIffIcult to tREAt And MultI-REsIstAnt
bActERIA
during the mid nineties 95-97% of all IAI associated
microbes were sensitive against commonly used antibi-
otics  (Group  2a  cephalosporins  with  metronidazole,
ciprofloxacin) [43], in recent years the share of resis-
tant species have increased worldwide [41, 44, 45]. Es-
pecially in postoperative and tertiary peritonitis as well
as with antibiotics pretreated necrotising pancreatitis,
one has to assume an involvement of resistant or diffi-
cult treatable bacteria (MRsA, vRE, Esbl-producer,
Pseudomonas spp. Acinetobacter spp. and carbapene-
mase-producing  organisms)  [12,  44,  45].  Individual
risk-constellations can also exist, if prior to the intra-
abdominal  infection,  antibiotic  treatments  occurred
(i.e. infected diabetic foot). In table 5 there is a de-
scription  of  different  species  and  treatment  recom-
mendations (table 5).
MRsA
Intra-abdominal  infections  with  MRsA  in  immuno-
competent  patients  are  very  rare.  In  most  cases
MRsA-colonisation follows after leaving the abdomen
open  (i.e.  intra-abdominal  compartment  syndrome).
non-compromised  patients  should  receive  antibiotic
treatment, if they show local or systemic inflammatory
signs  or  have  a  persistent  high  isolation  count.  All
post-transplantation  patients  with  iatrogenic  induced
immunodeficiency and evidence for MRsA (coloniza-
tion or infection) should be treated. tigecycline offers
among the new anti-MRsA sensitive antibiotics a li-
cense for IAI [8] and also covers the expected Gram-
negative and anaerobic spectrum. Recent clinical data
for  the  treatment  of  MdR-caused  complicated  IAI
with tigecycline showed clinical success rates between
75-80% [10-12]. If Pseudomonas spp. are found or sus-
pected  to  be  relevant  in  causing  the  infection,  a
Pseudomonas-active agent has to be added. linezolid
and daptomycin are solely active against Gram-posi-
tive bacteria [6, 7, 9]. compared to vancomycin, they
offer a good tissue penetration. clinical data for the
treatment of IAI with linezolid are available [9]. line-
zolid,  daptomycin  and  vancomycin  should  be  com-
bined with antibiotics covering Gram-negative species,
as intra-abdominal Gram-positive mono-infections are
rare [36]. data about community acquired MRsA-IAI
are currently not available. 
EntERococcI IncludInG vRE
Enterococci are an increasing cause of nosocomial in-
fections.  the  role  of  enterococci  as  the  primary
pathogen in multi-bacterial IAI is discussed controver-
sially, especially as a body of evidence is showing suc-
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treatments without enterococcal coverage [36, 37, 46].
Enterococci-covering antibiotics are recommended in
patients  with  post-operative  peritonitis,  tertiary  peri-
tonitis, severe sepsis of abdominal origin and antibiot-
ic  pretreatment  or  endocarditis-prone  patients  (Peri-
tonitis and heart valve replacement) [37]. In all these
indications  with  previous  antibiotic  treatment,  van-
comycin-resistant enterococci are likely to be encoun-
tered with E. faecium having greater pathogenic prop-
erties  than  E.  faecalis.  with  the  exception  of  van-
comycin, all previously mentioned antibiotics are ef-
fective against MRsA. Rare linezolid-resistant entero-
coccal strains have been described [47]. 
Esbl-PRoducInG PAtHoGEns
Recent years have shown a trend among Enterobacte-
riaceae species (especially e. coli, K. pneumoniae) to-
wards developing broad beta-lactamase-resistance in-
cluding group 3 and 4 cephalosporins, which are hy-
drolysed  by  so  called  extended-spectrum  beta-lacta-
mases (Esbl). A special role for the transmission of
Esbl-species seems to be the colonisation of the ani-
mal-  and  human  GI  tract  [48].  there  is  a  relatively
high prevalence of Esbl-producing species in visceral
surgical  departments  [49].  In  Esbl-infections  car-
bapenems and tigecycline are almost the only agents of
choice. Infections with strains resistant to carbapen-
ems,  fluoroquinolones  and  tobramycin  can  only  be
treated  with  either  tigecycline  or  colistin  [39,  40].
there is an urgency for the development of effective
new anti-Gram-negative agents.
PSeudomonAS sPP., AcinetobActer sPP.,
cARbAPEnEMAsE-PRoducInG bActERIA
Pseudomonas species are detected in about 8% of all
IAI,  whereas  the  percentage  of  causative  strains  is
likely to be much lower [50, 51]. basically group 3b
cephalosporins,  group  2-4  fluoroquinolones,  car-
bapenems,  piperacillin/tazobactam  and  aminoglyco-
sides are available, with combinations of above recom-
mended [52]. In the event that 4 or more usually avail-
able pseudomonas-active agents turn out to be ineffec-
tive (so called pan drug resistance (PdR)), colistin is
available for treatment although the data regarding the
treatment of PdR Pseudomonas infections are based
on nosocomial pneumonia and sepsis but not explicit-
ly for peritonitis [39, 40]. the same goes for carbapen-
emase-producing  pathogens  and  Acinetobacter
species,  where  tigecycline  and  colistin  are  the  only
treatment options. 
Especially  in  infections  caused  by  multi-resistant
bacteria, it is of paramount importance to anticipate
the spectrum of bacteria when initiating antimicrobial
therapy. If bacterial identification data and susceptibil-
ity patterns are not showing any resistant pathogens,
de-escalation should be performed.
IntRA-AbdoMInAl funGAl InfEctIons
Most  of  the  intra-abdominal  fungal  infections  are
caused by candida species. the prevalences of candi-
da-detection and infections on Icu's have increased in
the last 20 years. About 18% of all severe septic infec-
tions may be caused by candida species and of those
cases 25% are invasive intra-abdominal mycosis (IIM)
[20]. finding candida species in swabs obtained intra-
operatively seems to correlate with a higher lethality
[53]. the fact that diagnosing IIM through means oth-
er than blood cultures is very difficult might explain a
much higher prevalence. Proof of IIM is evidence for
candida spp.  from  intra-operatively  harvested  tissue
and, with caution, the microscopic and cultural detec-
tion in aspirated ascites [54]. sensitivity and specificity
of serological testing methods have improved, but can
not  be  relied  on  at  present  [55].  detecting  candida
species in tracheal secretions, urine culture or wound
secretions are usually uncomplicated colonisations not
warranting any treatment. the same is true for an in-
tra-operatively  harvested  positive  specimens  with
community acquired peritonitis (e.g. perforated stom-
ach ulcer). If the patient is immuno-competent and
stable, there is no requirement for antifungal therapy.
Prognosis of IIM is much worse with delayed treat-
ment  [54,  55].  High-risk  collectives  from  a  surgical
point of view include patients with severe postopera-
tive peritonitis (e.g.  anasto  motic leakage following
esophagojejunostomy), missed perforations (i.e. boer-
haave-syndrome) and patients with abdominal sepsis
with multiple tissue candida-infestation (i.e. positive
urine  culture  and  wound  secretion)  [54-56].  In  two
studies pre-emptive treatment with fluconazole signifi-
cantly reduced invasive fungal infections but failed to
reduce overall mortality compared to placebo [57, 58].
nevertheless, the value of preemptive antifungal treat-
ment is discussed controversial [53-55].
once IIM is suspected or proven, different antifun-
gals can be chosen from (see table 6). A high-dose-
therapy with fluconazole is sufficient for fluconazole-
susceptible  strains,  but  resistance  of  candida spp.
against  fluconazole  is  increasing  [59].  the  IdsA
guidelines  for  the  treatment  of  invasive  candidiasis
recommend, that patients, who are either instable or
have recently been given an azole therapy or prophy-
laxis, should initially receive an Echinocandin (anidula-
fungin, caspofungin, micafungin) [60]. If the isolated
candida spp. is fluconazole-susceptible, a step-down
therapy to fluconazole should be performed. 
because of its toxicity, amphotericin b is only rec-
ommended as primary therapy in cases of proven al-
lergic reactions toward other antifungals [60]. current-
ly a 14 day treatment period is regarded as sufficient,
as long as the clinical and haematological results are
improving [60]. finally it should be noted, that an in-
vasive intra-abdominal fungal infection can either be a
classic case of tertiary peritonitis, or a secondary peri-
tonitis with insufficient surgical source control [59]. In
the  last  case  a  surgical  intervention  with  successful
source control is the prerequisite for a successful anti-
fungal treatment. 
nEcRotIsInG PAncREAtItIs wItH InfEctEd
nEcRosIs
the severity of acute pancreatitis is measured by the
presence  or  absence  of  distant  organ  failure,  local
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to identify patients who are expected to developserious
complications,a sthese would require intensive monito  -
ring as well as possible surgical intervention. Pancreatic
necroses constitute a clinically relevant complication,
which can develop within the first few days of illness.
diagnosis is usually done through ct scanning. necro-
sis is associated with late complications (corrosive hae  -
mo  rrhages, organ perforations) and increased lethality
when they become infected. About 80% of all pancre-
atitis associated deaths are caused by septic complica-
tions.  the  translocation  of  colonic  bacteria  into  the
peripancreatic tissue is the most frequent cause of su-
perinfected  pancreatic  necroses.  Infected  pancreatic
necroses can be suspected, if (usually from week two
of illness) patients develop fever, leukocytosis, elevated
cRP-serum levels and an acute unexpected clinical de-
terioration.  the  visualisation  of  air  bubbles  within
necrotic tissue on ct scans is highly suggestive of in-
fection. In these and uncertain cases, an ultrasound- or
ct-guided fine needle aspiration should be obtained
and sent for laboratory testing (Gram-staining, micro-
biology), which could influence therapeutic strategy in
patients already treated with antibiotics [62]. 
the  treatments  available  for  infected  pancreatic
necroses are either conservative measures (endoscopi-
cally guided transgastral drainage, ct-guided drainage)
or surgical measures. A surgical intervention (open or
minimally invasive) is usually best performed after 2
weeks into the disease process, as earlier surgical inter-
ventions carry higher mortality risks [63]. 
until  recently,  prophylactic  administration  of  an-
tibiotics in necrotising pancreatitis was recommended
[64]. new scientific data have shown, that prophylactic
antibiotic treatments have no positive influence on the
course of illness [65, 66]. It is currently not recom-
mended to initiate antibiotic treatment in necrotizing
pancreatitis without infection [65-67]. A clear indica-
tion  for  antibacterial  treatment  is  in  all  cases  with
proven  infected  necroses,  infected  pseudo  cysts,  ab-
scess formation, cholangitis and other extra-pancreatic
infections. the most important bacteria involved in in-
fected pancreatic necroses are Enterobacteriaceae, En-
terococci,  staphylococci,  Anaerobes  and  candida
species. when choosing the appropriate antibiotic, it is
important not only to think about the spectrum but
also  about  adequate  pancreatic  tissue  penetration.
studies with reliable data for adequate tissue penetra-
tion exist for quinolones (ciprofloxacin, moxifloxacin),
carbapenems  (imipenem/cilastatin,  meropenem,  er-
tapenem,  doripenem),  metronidazole,  cephalosporins
(cefotaxime, ceftazidime, cefepim) and penicillins (me-
zlocillin,  piperacillin/tazobactam).  Insufficient  tissue
penetration is shown for aminoglycosides [24]. Possi-
ble antibiotic therapy regimes are found in table 7. In
suspected or proven infections with resistant species
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table 7. calculated antibiotic therapy with necrotising pancreatitis and secondary cholangitis. (blI= beta-lactamase inhibitors,
met.=Metronidazole, MRsA=Methicillin resistant s. aureus, vRE= vancomycin-resistant Enterococcus spp., Esbl= extended
spectrum beta-lactamase producing  species, #= combination with Pseudomonas-active antibiotics required if Pseudomonas is
suspected; *=use antibiotic only if local susceptibility rates are ≥90%.
Diagnosis Likely organism Initial therapy Level of evidence Strength of 
recommendation
Necrotizing pancreatitis  none none 1A
without infection
Necrotizing pancreatitis  Enterobacteriaceae Imipenem-cilastatin 1A
with infected necrosis Enterococci Meropenem 1A
staphylococci Ertapenem# 1A
Acylaminopenicillin/blI 1A
ciprofloxacin* + Met. 1b
levofloxacin* + Met. 1b
cephalosporin group 2  1b
+ Metronidazole
MRsA
vRE see table 5
Esbl
candida spp. see table 6
Secondary cholangitis Enterobacteriaceae  Aminopenicillin/blI 1A
Enterococci  ciprofloxacin* + Met. 1b
Anaerobes levofloxacin* + Met. 1b
Acylaminopenicillin/blI 1A
ceftriaxon 1b
Imipenem-cilastatin 1A
Meropenem 1A
Ertapenem# 1A
cefepime 3b
Pseudomonas spp. see table 5
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tant bacteria are shown in table 5, for fungal infec-
tions in table 6. 
sEcondARy cHolAnGItIs
Infection of the biliary ductal system is usually caused
by  biliary  obstruction.  causes  are  usually  gallstones,
benign  structures  and  rarely  tumorous  obstructions
(usually sterile). with the increase of obstruction, the
probability of cholangitis raises with the possibility of
systemic  bacteremia.  A  positive  bile  duct  culture  is
found in about 75 to 100% in biliary obstruction. the
bacterial  spectrum  includes  Enterobacteriacea,  Ente-
rococci and Anaerobes. In postoperative bacteremia,
cholangiogenic sepsis, subhepatic abscesses and inter-
ventional approaches (ERcP or endoscopic papilloto-
my), other Gram-negative bacilli and Pseudomonas are
encountered. 
Primary therapy for choledocholithiasis is clearing
the biliary system via ERc with consecutive laparo-
scopic  cholecystectomy  (so  called  therapeutic  split-
ting). obstructive cholangitis secondary to gallstones,
should even in septic conditions be treated by endo-
scopic removal of stones. Inoperable tumours can also
be successfully treated with stent-implants. A calculat-
ed  antibiotic  therapy  can  be  started  with  either
Aminopenicillin/blI,  Acylaminopenicillin/blI  or  a
group  3  or  4  cephalosporin  in  combination  with
Metronidazole. Alternatively group 1 or 2 carbapen-
ems or group 2 or 3 fluoroquinolones are administrat-
ed (table 7). If Pseudomonas spp. is involved or sus-
pected,  a  relevant  Pseudomonas-sensitive  substance
should be added [35]. 
clostRIdIuM-dIffIcIlE AssocIAtEd colItIs
Metronidazole  and  vancomycin  are  the  agents  of
choice for the treatment of clostridium difficile infec-
tion (cdI). Initial cure rates of >90% have been re-
ported. fulminant or complicated severe cdI and re-
current  cdI  are  matters  of  concern.  Recommenda-
tions for the treatment of clostridium difficile infec-
tions have recently been published by [69].
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